FDA approves Lundbeck’s VYEPTI™ (eptinezumab-jjmr) – the first and only intravenous preventive treatment for migraine

Lundbeck today announced that VYEPTI™ (eptinezumab-jjmr) has been approved by the U.S. Food and Drug Administration (FDA) for the preventive treatment of migraine in adults and will be available in April 2020. The recommended dose is 100 mg every 3 months; some patients may benefit from a dose of 300 mg. VYEPTI is the first FDA-approved intravenous (IV) treatment for migraine prevention.

Read More: https://newsroom.lundbeckus.com/news-release/2020/fda-approves-lundbecks-vyepti-eptinezumab-jjmr-for-migraine